Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or unknown causes. Some common types of ILD are sarcoidosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and eosinophilic pneumonia. ILD can cause symptoms such as shortness of breath, dry cough, fatigue, and chest pain. The diagnosis of ILD is based on medical history, physical examination, chest imaging, lung function tests, and sometimes lung biopsy. The treatment of ILD depends on the specific type and cause of the disease, but may include corticosteroids, immunosuppressants, antifibrotics, oxygen therapy, pulmonary rehabilitation, or lung transplantation. ILD is a chronic and progressive condition that can affect the quality of life and survival of patients.
The Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 40 molecules, with 40 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acrobat Genomics IncAdAlta Ltd
Adiso Therapeutics Inc
Aerami Therapeutics Inc
Amplia Therapeutics Ltd
AnaMar AB
aTyr Pharma Inc
Avalyn Pharma Inc
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Changchun GeneScience Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp.
CSL Ltd
Daewoong Pharmaceutical Co Ltd
EmphyCorp Inc
F. Hoffmann-La Roche Ltd
FibroBiologics Inc
Fibrotherapeutics Inc
Foresee Pharmaceuticals Co Ltd
Genentech USA Inc
GNI Group Ltd
Halo Biosciences Inc
HEC Pharma Co Ltd
Insmed Inc
Kiox Pharmaceuticals ApS
KYORIN Pharmaceutical Co Ltd
Lassen Therapeutics 1 Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Mochida Pharmaceutical Co Ltd
Pharmosa Biopharm Inc
Puretech Health Plc
R-Pharm
Redx Pharma Plc
Saje Pharma LLC
Taiho Pharmaceutical Co Ltd
Zephyrm Biotechnologies Co Ltd
Table of Contents
Table
Figures
Frequently asked questions